TriangleFHD-286 (NCT07551635)
FHD-286 trial for Small Cell Lung Cancer (NCT07551635). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with extensive-stage small-cell lung cancer that progressed or returned after platinum chemotherapy. More than 50% POU2F3 expression on tissue staining is required. Previous SMARCA2/4-inhibitor treatment is excluded.
The idea: take FHD-286 capsules daily in 21-day cycles. It blocks SMARCA4/2 components of a complex that controls DNA packaging and gene activity, aiming to disrupt cancer growth. Researchers assess tumor response and side effects. Symptomatic brain metastases exclude participation.
This phase 2 study plans 20 patients. Alissa Cooper leads at Dana-Farber in Boston, the sole recruiting US location.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.